Shots:
- Nicox has granted Kowa exclusive global rights to develop & commercialize NCX 470 for glaucoma or ocular hypertension, excl. territories already licensed to Ocumension (China, Korea & Southeast Asia) & to Kowa (Japan)
- As per the deal, Nicox will receive $8.7M (€7.5M) upfront & near-term milestones tied to positive topline P-III (Denali) trial data (expected mid-Aug to mid-Sep 2025) & FDA’s NDA filing (in H2’26), with total milestones of $147.5M (€127M) or $222.5 (€191.5M) based on trial outcome, plus tiered royalties up to 20% in the US & single to double-digit % ex-US
- Nicox will fund remaining development work, mainly PK studies, & support Kowa in NDA preparation, while Kowa handles all other development, regulatory, & commercialization efforts
Ref: Globenewswire | Image: Nicox and Kowa | Press Release
Related News:- Bio-Thera Solutions and SteinCares Broaden Collaboration to Commercialize (Biosimilar, Dupilumab) in Latin America
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
